(Q37261956)

19 August 2017

1 reference

title

Why does androgen deprivation enhance the results of radiation therapy? (English)

1 reference

19 August 2017

0 references

Jennifer Y Wo

1

1 reference

PubMed ID

18774467

19 August 2017

Anthony L Zietman

series ordinal

2

1 reference

19 August 2017

1 September 2008

1 reference

19 August 2017

1 reference

19 August 2017

26

1 reference

19 August 2017

522-529

1 reference

19 August 2017

5

1 reference

STUDIES ON PROSTATIC CANCER

19 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Tr

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Neoadjuvant hormonal therapy: the Canadian experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Hormonal treatment before radical prostatectomy: a 3-year followup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Transperineal interstitial permanent prostate brachytherapy for carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Hypoxia-inducible factor 1: master regulator of O2 homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

Expectant management with selective delayed intervention for favorable risk prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.008

10.1016/J.UROLONC.2008.03.008

7 January 2021

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jyuk7hiql5cevdygho3doza3oa

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_jyuk7hiql5cevdygho3doza3oa

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jyuk7hiql5cevdygho3doza3oa

mapped directly with Wikidata item

30 July 2022

based on heuristic

1 reference

https://api.fatcat.wiki/v0/release/jyuk7hiql5cevdygho3doza3oa